Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.125p -0.40% 30.875p 30.50p 31.25p 31.00p 30.875p 31.00p 120,823 16:20:59
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 48.5 -12.1 -2.3 - 183.43

Allergy Therapeutics Share Discussion Threads

Showing 3401 to 3424 of 3425 messages
Chat Pages: 137  136  135  134  133  132  131  130  129  128  127  126  Older
DateSubjectAuthorDiscuss
19/7/2017
08:21
Approaching 35p by the end of the day would be good!
audigger
18/7/2017
19:52
This was off target....updated to approaching 40p by October lol Depending on the trials news. jimmyloser 26 Jun '17 - 20:59 - 3270 of 3291 0 0 Edit Into the thirties this side of October and the rest is beyond my crystal ball. lol
jimmyloser
18/7/2017
19:42
Hop on the fun bus
richtea2517
18/7/2017
16:34
Great day and truly deserved for the hard work put in here. I see Finncap have upped their target, fwiw, so has jimmyloser!
jimmyloser
18/7/2017
11:53
finnCap up their target to 46p from 43p
shauney2
18/7/2017
07:44
Impressive performance. Lets hope the share price can replicate this!
audigger
18/7/2017
07:23
Well done and thanks to all at AGY. You will not see many updates better than that one!
jimmyloser
12/7/2017
13:25
Not what it seems. It was me that took the price down by moving from one account to another this morning.
jimmyloser
12/7/2017
13:06
Clearly not!
audigger
11/7/2017
12:22
It could well be................... 17 07 2017 Trading update
jimmyloser
11/7/2017
10:07
Are seeing the start of a rally ahead of next week's trading update?
audigger
06/7/2017
07:48
Excellent. The potential of these adjuvants is huge.
audigger
06/7/2017
07:09
NON RNS Alert Allergy Therapeutics PLC Publication of adjuvant studies in journals 06/07/2017 7:00am RNS Non-Regulatory Allergy Therapeutics PLC 06 July 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Two studies of adjuvants in malaria and influenza vaccines published in peer-reviewed journals Publications demonstrate the potential of Allergy Therapeutics' novel adjuvant systems in infectious diseases, further broadening the product pipeline 6 July 2017 Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces that two preclinical studies carried out through its Bencard Adjuvant Systems division have been published in peer-review journals. The two papers report that the novel depot adjuvant behind Allergy Therapeutics' successful allergy immunotherapy Pollinex(R) platform, microcrystalline tyrosine (MCT), both alone and in an adjuvant system, have broad applications and elicit high, sustained antibody titres demonstrating enhanced protective efficacy compared to conventional adjuvants including aluminium. Commenting on the recent publications, Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, said: "These publications underpin the strategy for our Bencard Adjuvant Systems division, which focuses on extending the use of MCT(R) and VLP in further developing vaccines against unmet needs, and new and emerging infectious diseases that require an effective depot adjuvant." The two publications are: Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza: Heath et al., BMC Infectious Diseases (2017) 17:232 The paper authored by principal scientist Dr Matthew D. Heath & collaborators from Public Health England discusses the use of MCT(R) in a seasonal influenza vaccine model. The use of MCT(R) displayed higher binding affinity compared to the conventional depot adjuvant, aluminium, demonstrating the suitability of MCT(R) as a depot adjuvant in applications outside of allergy immunotherapy. MCT(R) elicited an immune response (HAI titre) indicative of protection in a pre-clinical model. The data provide evidence of the suitability of using the MCT(R) platform in an influenza model and address some of the issues associated with weakly stimulating vaccine targets/antigens. Virus-like particle (VLP) plus microcrystalline tyrosine (MCT) adjuvants enhance vaccine efficacy improving T and B cell immunogenicity and protection against plasmodium berghei/vivax: Cabral-Miranda et al., Vaccines (2017) 5;10. This publication authored with The Jenner Institute at the University of Oxford has been published investigating the use of adjuvants MCT and adjuvant system MCT+VLP (AdSys-VCT) in malaria. In a pre-clinical model, malaria antigens conjugated to VLP and formulated in MCT induced highest antibody responses, highest T-cell responses, and offered the best protection against malaria compared with antigens formulated with aluminium. Moreover, the study demonstrated that MCT(R) alone is able to elicit high and sustained IgG antibody responses that are specific and protective against P.vivax (malaria).
jimmyloser
27/6/2017
17:34
We shall see. At least the timing of my top-up looks to have been good for once! As FarmerG mentioned yesterday, it would be good to see some clarity on timing particularly for the US, accepting all the caveats and uncertainties...
audigger
27/6/2017
15:11
AuDigger I think that they had a good lunch.....I smell something good, do you? 30p by October may well be off the mark by a mile!!! lol
jimmyloser
27/6/2017
11:35
Makes a lot of sense.
audigger
27/6/2017
09:15
Now we know why we had that oddball RNS last week............the visitors will most likely hear that the trials are going well at this time. No inside information! There is always a reason. impo/dyor etc
jimmyloser
27/6/2017
08:34
Need to prove the product first I would have thought!
jimmyloser
27/6/2017
07:55
Or a partner for their US opportunity
audigger
27/6/2017
07:36
or the early shots in further fund raising! which we all know will be required. Good stuff.
jimmyloser
27/6/2017
07:31
Well today's announcement could be the firing pistol towards 30p as it looks like they are embarking on some serious investor engagement. Has the makings of a communication strategy!
audigger
26/6/2017
21:01
That will do ;-).
farmergeorge
26/6/2017
20:59
Into the thirties this side of October and the rest is beyond my crystal ball. lol
jimmyloser
26/6/2017
20:28
Yes, very encouraging. Now, the question is, what are the time scales?
farmergeorge
Chat Pages: 137  136  135  134  133  132  131  130  129  128  127  126  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20170724 22:38:58